Afferent制药公司在2016年胸科协会国际会议上展示AF-219治疗慢性咳嗽的Ph2b期积极临床数据.docx

Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society (ATS) International ConferenceAfferent制药公司在2016年胸科协会国际会议上展示AF-219治疗慢性咳嗽的Ph2b期积极临床数据SAN FRANCISCO--(BUSINESS WIRE)--Afferent Pharmaceuticals, a leader in the development of small molecule compounds targeting the P2X3 receptor for the treatment of poorly managed and common neurogenic conditions, today announced that AF-219 significantly reduced cough frequency in the first cohort of a two cohort-Phase 2b study dose-escalation clinical trial in chronic cough patients. Results demonstrated that all AF-219 doses, including the lowest dose of 50 mg twice daily, demonstrated a statistically significant reduction in awake cough frequency compared to placebo (p≤0.002). AF-219 is a selective, non-centrally-acting and orally administered P2X3 antagonist that targets the mechanism by which certain nerve fibers become hyper-sensitized and can lead to chronic and debilitating symptoms, such as chronic cough. Chronic cough is defined as a cough lasting more than eight weeks. Data were presented at the American Thoracic Society (ATS) International Conference, held May 13-18, 2016 in San Francisco.【Afferent 制药公司今天宣布AF-219在一个两队列的Ph2期剂量递增临床试验研究中，能显著降低第一队列慢性咳嗽患者的咳嗽频率。结果表明AF-219的所有剂量，包括每日低剂量的50mg，相比对照均能显著降低夜间咳醒的频率。AF-219是选择性、非中枢作用、口服P2X3受体拮抗剂，开发用于治疗以某种神经变得超敏从而导致慢性和衰弱的症状包括咳嗽。慢性咳嗽被定义为咳嗽持续八周以上。数据在2016年5月13-18日的美国胸科学会（ATS）国际会议上提出。】Data from the second cohort of the Phase 2b study, which evaluates lower doses of AF-219 (as low as 7.5 mg BID), are expected to be presented at a medical/scientific conference in the second half of 2016.【Ph2b期第二队列是评估低剂量AF-219（低至7.5 mg BID）的疗效情况，将在2016年后半年的医疗/科学会议上展出。】These data support continued clinical development of AF-219 and complement the initial proof-of-concept study showing similar efficacy results in this unmet condition. The company anticipates beginning a Phase 3 registration program in early 2017.【这些数据将为AF-219